Terug

H. Lundbeck A/S

Datakwaliteit: 100%

Oversold

HLUBF

OTC Healthcare Drug Manufacturers - Specialty & Generic

€ 4,82

€ 0,00 (0,00%)

Marktkapitalisatie: 4,78B

Ook genoteerd als HLBBF OTC

Dagbereik

€ 4,82 € 5,37

52-Weeksbereik

€ 3,67 € 6,41

Volume

50D / 200D Gem.

€ 5,61 / € 5,13

Vorige Slotkoers

€ 4,82

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek	Aandeel	Sector Mediaan
P/E	1,5	0,4
P/B	0,2	2,9
ROE %	12,8	3,7
Net Margin %	13,1	3,9
Rev Growth 5Y %	10,5	10,0
D/E	0,5	0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode	WPA Sch.	Omzet Sch.	Analisten
FY2027	€ 0,00 € 0,00 – € 0,00	26 B	0
FY2026	€ 0,00 € 0,00 – € 0,00	25 B	0

Belangrijkste Punten

Revenue grew 10,50% annually over 5 years — strong growth

ROE of 12,78% — decent returns on equity

Debt/Equity of 0,48 — conservative balance sheet

Generating 4,33B in free cash flow

P/E of 1,50 — trading at a low valuation

Cash machine — converts 136,09% of earnings into free cash flow

Groei

Revenue Growth (5Y)

10,50%

Revenue (1Y)10,42%

Earnings (1Y)1,33%

FCF Growth (3Y)10,05%

Kwaliteit

Return on Equity

12,78%

ROIC12,87%

Net Margin13,11%

Op. Margin26,05%

Veiligheid

Debt / Equity

0,48

Current Ratio1,44

Interest Coverage11,72

Waardering

P/E Ratio

1,50

P/B Ratio0,19

EV/EBITDA2,11

Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	10,42%	Revenue Growth (3Y)	10,46%
Earnings Growth (1Y)	1,33%	Earnings Growth (3Y)	17,93%
Revenue Growth (5Y)	10,50%	Earnings Growth (5Y)	24,68%
Profitability
Revenue (TTM)	24,30B	Net Income (TTM)	3,18B
ROE	12,78%	ROA	5,91%
Gross Margin	79,58%	Operating Margin	26,05%
Net Margin	13,11%	Free Cash Flow (TTM)	4,33B
ROIC	12,87%	FCF Growth (3Y)	10,05%
Safety
Debt / Equity	0,48	Current Ratio	1,44
Interest Coverage	11,72	Dividend Yield	0,03%
Valuation
P/E Ratio	1,50	P/B Ratio	0,19
P/S Ratio	0,20	PEG Ratio	8,40
EV/EBITDA	2,11	Dividend Yield	0,03%
Market Cap	4,78B	Enterprise Value	13,37B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	24,30B	22,00B	19,91B	18,25B	16,30B
Net Income	3,18B	3,14B	2,29B	1,92B	1,32B
EPS (Diluted)	3,21	3,17	2,31	1,93	1,33
Gross Profit	19,33B	17,77B	15,43B	14,30B	12,65B
Operating Income	6,33B	3,27B	3,20B	2,85B	2,01B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	53,89B	56,98B	37,41B	37,45B	34,65B
Total Liabilities	29,04B	31,97B	15,36B	16,67B	16,37B
Shareholders' Equity	24,85B	25,01B	22,05B	20,78B	18,28B
Total Debt	12,02B	16,69B	4,15B	5,58B	5,32B
Cash & Equivalents	3,43B	4,66B	5,01B	3,42B	2,28B
Current Assets	12,75B	13,01B	13,29B	11,41B	8,61B
Current Liabilities	8,83B	8,58B	7,99B	8,20B	8,82B

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Cash Flow Compounder

#169 of 1024

Custom Deep Value Investing (Seth Klarman)

#376 of 820

Growth Price/Sales Ratio Focus (Ken Fisher)

#438 of 616

Value Defensive Investing (Benjamin Graham)

#396 of 708

Recente Activiteit

Ingestapt Cash Flow Compounder

Mar 24, 2026

Ingestapt Deep Value Investing (Seth Klarman)

Mar 24, 2026

Ingestapt Price/Sales Ratio Focus (Ken Fisher)

Mar 24, 2026

Ingestapt Defensive Investing (Benjamin Graham)

Mar 24, 2026